The Endocannabinoid System and CBD Receptors
The endogenous cannabinoid system has been described as “an ancient lipid signaling network which in mammals modulates neuronal functions, inflammatory processes, and is involved in the etiology of certain human lifestyle diseases, such as Crohn’s disease, atherosclerosis and osteoarthritis. The system is able to downregulate stress-related signals that lead to chronic inflammation and certain types of pain, but it is also involved in causing inflammation-associated symptoms, depending on the physiological context.
CB1 Receptors
The CB1 receptor has been cloned from humans. Activation of CB1 receptors leads to dose-dependent and stereo-selective inhibition of adenylate cyclase activity, thus affecting memory, perception, and movement. The CB1 receptor appears to be responsible for the mood-enhancing effects of Cannabis as well as negative, dysphoria-inducing, and frank psychotomimetic effects in susceptible individuals. CB1 receptor distribution has been well characterized in the human brain. The receptors are expressed in high abundance in the hippocampus and associational cortical regions, the cerebellum, and the basal ganglia. This widespread distribution in the brain matches well with the known pharmacodynamic effects of cannabinoids. In contrast, binding is sparse or absent from the brain stem, medulla, and thalamus. The paucity of CB1 receptors in these areas helps explain the absence of life-threatening effects on vital physiological functions associated with extremely high doses of cannabinoids. Besides the brain, the CB1 receptor occurs in the testis, and presynaptically on sympathetic nerve terminals. CB1 receptor mRNA has been identified in the adrenal gland, heart, lung, prostrate, bone marrow, thymus, and tonsils.
CB2 Receptors
Although CB1 and CB2 receptors share considerable structural similarities, their distribution and activity diverge. Among other actions, including pain modulation, CB2 receptors are thought to serve an important role in immune function and inflammation. There is ample evidence that CB2 receptor activation reduces nociception in a variety of preclinical models, including those involving tactile and thermal allodynia, mechanical and thermal hyperalgesia, and writhing. With regard to their role in modulating neuropathic pain, the presence of CB2 receptors on microglia within the nervous system may explain the putative benefits of cannabinoids in reducing cytokine-mediated neuroinflammation. CB1 and CB2 receptors inhibit adenylate cyclase via interactions at the G-protein complex. However, their activation and consequent inhibition of various ion channels differs. The key point is that differential binding of CB1 or CB2 receptors, either separately or in combination by their respective endogenous or exogenous ligands, leads to varied physiological effects, mediated via several neurotransmitters, including acetylcholine, glutamate, and dopamine.
The endogenous cannabinoid system has been described as “an ancient lipid signaling network which in mammals modulates neuronal functions, inflammatory processes, and is involved in the etiology of certain human lifestyle diseases, such as Crohn’s disease, atherosclerosis and osteoarthritis. The system is able to downregulate stress-related signals that lead to chronic inflammation and certain types of pain, but it is also involved in causing inflammation-associated symptoms, depending on the physiological context.
CB1 Receptors
The CB1 receptor has been cloned from humans. Activation of CB1 receptors leads to dose-dependent and stereo-selective inhibition of adenylate cyclase activity, thus affecting memory, perception, and movement. The CB1 receptor appears to be responsible for the mood-enhancing effects of Cannabis as well as negative, dysphoria-inducing, and frank psychotomimetic effects in susceptible individuals. CB1 receptor distribution has been well characterized in the human brain. The receptors are expressed in high abundance in the hippocampus and associational cortical regions, the cerebellum, and the basal ganglia. This widespread distribution in the brain matches well with the known pharmacodynamic effects of cannabinoids. In contrast, binding is sparse or absent from the brain stem, medulla, and thalamus. The paucity of CB1 receptors in these areas helps explain the absence of life-threatening effects on vital physiological functions associated with extremely high doses of cannabinoids. Besides the brain, the CB1 receptor occurs in the testis, and presynaptically on sympathetic nerve terminals. CB1 receptor mRNA has been identified in the adrenal gland, heart, lung, prostrate, bone marrow, thymus, and tonsils.
CB2 Receptors
Although CB1 and CB2 receptors share considerable structural similarities, their distribution and activity diverge. Among other actions, including pain modulation, CB2 receptors are thought to serve an important role in immune function and inflammation. There is ample evidence that CB2 receptor activation reduces nociception in a variety of preclinical models, including those involving tactile and thermal allodynia, mechanical and thermal hyperalgesia, and writhing. With regard to their role in modulating neuropathic pain, the presence of CB2 receptors on microglia within the nervous system may explain the putative benefits of cannabinoids in reducing cytokine-mediated neuroinflammation. CB1 and CB2 receptors inhibit adenylate cyclase via interactions at the G-protein complex. However, their activation and consequent inhibition of various ion channels differs. The key point is that differential binding of CB1 or CB2 receptors, either separately or in combination by their respective endogenous or exogenous ligands, leads to varied physiological effects, mediated via several neurotransmitters, including acetylcholine, glutamate, and dopamine.
Cannabidiol (CBD)
Cannabidiol proven benefits as adjuvant therapy, it is not a cure:
- Anti-inflammatory effects on soft tissue, muscular-skeletal and nervous system
- Aids with intestine digestion
- Helps balances gut bacterial flora
- Improves nervous system (from headaches to seizures and tremors)
- Help boost the immune system
- Scientific-proven anti-proliferative effect on tumors
- Bronchodilatation effect in lungs (asthma, COPD)
- Vasodilatation effect on blood vessels (blood pressure)
- Increases oxygen in all tissues
- Helps recovery from ischemic tissue damage
- Stress reliever
- Mood stabilizer
- Aids with allograft acceptance
- Helps bone mineralization of calcium
Delta-8 tetrahydrocannabinol (Delta-8 TCH)
First of all, consult your physician before using Hemp Delta-8 gummies.
Hemp Delta-8 THC may not be legal or is banned in Utah, Rhode Island, Montana, Mississippi, Iowa, Idaho, Delaware, Colorado, Arkansas, Arizona, and Alaska. Will not ship these products to these States.
Delta-8 gummies may cause drowsiness similar to over-the-counter Benadryl (Diphenhydramine). Consumption of this product may impair your ability to drive or operate heavy machinery. Do not use if under 18 years old, pregnant or breastfeeding; unless evaluated and recommended otherwise by a physician. Use extreme caution when using this product if you are trying a THC product for your very first time.
Delta-8 Gummies may help alleviate the following acute symptoms or medical conditions:
- Pain
- Insomnia
- Nauseas
- Lack of appetite
- Muscles spasms
- Anxiety
- Glaucoma
- It is an anti-oxidant, do not use if receiving radiation therapy
Does the use of Hemp-derived Delta-8 products show up on a drug test?
Yes. Hemp-derived Delta-8 THC will show up positive for tetrahydrocannabinol just like Delta-9 THC from marijuana.
CBG, CBN, CBC and other cannabinoids
Our Full Spectrum Capsules have all cannabinoids present; CBD, CBG, CBN and CBC.
Cannabigerol (CBG)
- Vasodilatation effect
- Neuroprotection effect
- Improves intraocular pressure in glaucoma
- Improves inflammatory bowel syndrome
- Scientific-proven anti-proliferative effect on tumors
- Anti-bacterial effect
- Helps with urinary bladder dysfunction
Cannabinol (CBN)
- Anti-inflammatory effect in arthritis
- Antibacterial effect
- Calming effect
- Neuroprotection effect
- Appetite stimulant
Cannabichromene (CBC)
- Anti-inflammatory effect in arthritis
- Promotes healthy brain function
- Helps with acne
- Anti-depressive effect
Tetrahydrocannabivarin (THCV)
- Appetite suppressant
- Balances sugar levels
- Improves insulin resistance
- Anxiolytic effect
- Stimulates bone growth
- Improves memory loss
Cannabinoids and Pain
Evidence continues to accumulate suggesting that cannabinoids can impact normal inhibitory pathways and pathophysiological processes influencing nociception in humans. When cannabinoids do have an analgesic effect, it is more likely to occur in hyperalgesic and inflammatory states. Clinical trials lasting from days to months, involving more than 1,000 patients, have shown efficacy in different categories of chronic pain conditions, but the vast majority of controlled trials have involved patients with chronic neuropathic pain.